Topics and Expertise: QBI Coronavirus Research Group

Findings from QBI point to a host of viral proteins that enable SARS-CoV-2 variants to evade the immune system.

“If you get a drug that targets a human protein, it would be incredibly hard for the virus to mutate away from being reliant on it,” said Nevan Krogan, the director of QBI.

“This is looking across coronaviruses and finding the commonalities so we’re in a better position to attack SARS3 when it comes,” said Nevan Krogan, the director of QBI.

School scientists developed an antiviral that fights SARS-CoV-2 that can be given as a nasal spray.

The chemical fragments could bind to and disable an enzyme that helps the virus replicate.

UCSF-led collaboration uncovers new avenues for COVID-19 drug discovery

The QBI Coronavirus Research Group found six drugs that effectively beat back SARS-COV-2 in the laboratory.

The UCSF Quantitative Biosciences Institute has made headway identifying dozens of potential therapies for the COVID-19 outbreak.

The chief operating officer of the Quantitative Biosciences Institute (QBI) shares a view of the team's work on COVID-19.